



4 October 2024

ASX Announcement

Island (ASX: ILA) investor webinar invitation

MELBOURNE Australia, 4 October 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to invite investors to an online briefing session on Tuesday, 8 October 2024, at 10.30am AEDT.

During this briefing, Island CEO and Managing Director, Dr David Foster, will provide an update on the ISLA-101 Phase 2a/b PROTECT clinical trial, which has now dosed subjects in the Phase 2a prophylactic arm. Dr Foster will also discuss the recent Placement and explain how the new funds will be used to support both Island's clinical program and pipeline expansion plans. This presentation will then be followed by a Q&A session.

To attend the webinar, please pre-register via the following link:
https://us02web.zoom.us/webinar/register/WN_B4gPTEpUSUqQ7Ot3oZmMww#/registration

To subscribe to Island's monthly newsletter, [IslandWatch](#), and other forms of email communications, please visit [this page](#) of our website.

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed



for the prevention and treatment of dengue² fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to

expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.